INS and type 2 diabetes mellitus: For patients with advanced uncontrolled T2D already receiving insulin, subcutaneous semaglutide (0.5 mg and 1.0 mg) and oral semaglutide (7 mg and 14 mg) both reduced HbA1c significantly more than placebo (p < 0.001) (Figure 1D) (20, 26).